Colleges
Adrian Hill
Director of the Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, Professor of Human Genetics
Vaccines for malaria and other major diseases
Adrian V. S. Hill KBE, FRCP, FRS is the Lakshmi Mittal Professor of Vaccinology and Director of the Jenner Institute at Oxford University. In 2005 he founded the Jenner Institute at Oxford, which is now one of the largest academic vaccine centres globally with clinical-stage vaccine programmes against fifteen diseases.
His current lead malaria vaccine, R21 in matrix-M adjuvant, has shown high efficacy in clinical trials in the UK and Africa (Lancet. 2021;397:1809-1818) and could be the first widely used vaccine to impact on the great disease burden of malaria in Africa.
In Q1 2020, the Jenner Institute initiated a major effort towards rapid development of a COVID-19 vaccine which in collaboration with AstraZeneca is now in world-wide pandemic deployment.
He has published over 600 research papers with 60,000 citations and co-founded several spin-off companies. He is a Fellow of the UK Academy of Medical Sciences, the Royal College of Physicians and the Royal Society.
Recent publications
-
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Journal article
Dold C. et al, (2025), Science Translational Medicine, 17
-
A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against Mycobacterium avium complex subspecies in patients with active Crohn's disease
Journal article
Sanderson J. et al, (2025), eBioMedicine, 113
-
Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context.
Journal article
Diawara H. et al, (2025), BMJ global health, 10
-
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.
Journal article
Varley M. et al, (2025), BMJ open, 15
-
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Journal article
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868